366 related articles for article (PubMed ID: 27234729)
41. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads.
Amico P; Hönger G; Mayr M; Steiger J; Hopfer H; Schaub S
Transplantation; 2009 Jun; 87(11):1681-8. PubMed ID: 19502960
[TBL] [Abstract][Full Text] [Related]
42. Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation.
Smith JD; Ibrahim MW; Newell H; Danskine AJ; Soresi S; Burke MM; Rose ML; Carby M
J Heart Lung Transplant; 2014 Oct; 33(10):1074-82. PubMed ID: 24954882
[TBL] [Abstract][Full Text] [Related]
43. Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection.
Viglietti D; Bouatou Y; Kheav VD; Aubert O; Suberbielle-Boissel C; Glotz D; Legendre C; Taupin JL; Zeevi A; Loupy A; Lefaucheur C
Kidney Int; 2018 Oct; 94(4):773-787. PubMed ID: 29801667
[TBL] [Abstract][Full Text] [Related]
44. Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry cross-matches.
Kwon H; Kim YH; Choi JY; Shin S; Jung JH; Park SK; Han DJ
Clin Transplant; 2018 Jun; 32(6):e13266. PubMed ID: 29676812
[TBL] [Abstract][Full Text] [Related]
45. Serum flow cytometric C1q binding antibody analysis of renal recipients with low levels of sensitization.
Ata P; Canbakan M; Kara M; Özel L; Ünal E; Titiz Mİ
Transplant Proc; 2012; 44(6):1652-5. PubMed ID: 22841237
[TBL] [Abstract][Full Text] [Related]
46. C1q-fixing human leukocyte antigen assay in immunized renal patients: correlation between Luminex SAB-C1q and SAB-IgG.
Llorente S; Boix F; Eguia J; López M; Bosch A; Martinez H; Gonzalez MJ; López-Hernández R; Salgado G; Moya-Quiles MR; Campillo JA; García-Alonso AM; Minguela A; Jimeno L; Alvarez-López MR; Muro M
Transplant Proc; 2012 Nov; 44(9):2535-7. PubMed ID: 23146446
[TBL] [Abstract][Full Text] [Related]
47. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
[TBL] [Abstract][Full Text] [Related]
48. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.
Tait BD; Süsal C; Gebel HM; Nickerson PW; Zachary AA; Claas FH; Reed EF; Bray RA; Campbell P; Chapman JR; Coates PT; Colvin RB; Cozzi E; Doxiadis II; Fuggle SV; Gill J; Glotz D; Lachmann N; Mohanakumar T; Suciu-Foca N; Sumitran-Holgersson S; Tanabe K; Taylor CJ; Tyan DB; Webster A; Zeevi A; Opelz G
Transplantation; 2013 Jan; 95(1):19-47. PubMed ID: 23238534
[TBL] [Abstract][Full Text] [Related]
49. C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort study.
Moktefi A; Parisot J; Desvaux D; Canoui-Poitrine F; Brocheriou I; Peltier J; Audard V; Kofman T; Suberbielle C; Lang P; Rondeau E; Grimbert P; Matignon M
Transpl Int; 2017 Mar; 30(3):277-287. PubMed ID: 27992962
[TBL] [Abstract][Full Text] [Related]
50. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
51. Graft immunologic events in deceased donor kidney transplant recipients with preformed HLA-donor specific antibodies.
Ixtlapale-Carmona X; Arvizu A; De-Santiago A; González-Tableros N; López M; Castelán N; Marino LA; Uribe-Uribe NO; Contreras AG; Vilatobá M; Morales-Buenrostro LE; Alberú J
Transpl Immunol; 2018 Feb; 46():8-13. PubMed ID: 28974434
[TBL] [Abstract][Full Text] [Related]
52. Association between post-transplant donor-specific antibodies and recipient outcomes in simultaneous liver-kidney transplant recipients: single-center, cohort study.
Yazawa M; Cseprekal O; Helmick RA; Talwar M; Balaraman V; Podila PSB; Agbim UA; Maliakkal B; Fossey S; Satapathy SK; Sumida K; Kovesdy CP; Nair S; Eason JD; Molnar MZ
Transpl Int; 2020 Feb; 33(2):202-215. PubMed ID: 31647143
[TBL] [Abstract][Full Text] [Related]
53. Effect of C1q-binding donor-specific anti-HLA antibodies on the clinical outcomes of patients after renal transplantation: A systematic review and meta-analysis.
Kang ZY; Liu C; Liu W; Li DH
Transpl Immunol; 2022 Jun; 72():101566. PubMed ID: 35257893
[TBL] [Abstract][Full Text] [Related]
54. De novo donor-specific anti-HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q-binding ability.
Kauke T; Oberhauser C; Lin V; Coenen M; Fischereder M; Dick A; Schoenermarck U; Guba M; Andrassy J; Werner J; Meiser B; Angele M; Stangl M; Habicht A
Transpl Int; 2017 Apr; 30(4):360-370. PubMed ID: 27862352
[TBL] [Abstract][Full Text] [Related]
55. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation.
Riethmüller S; Ferrari-Lacraz S; Müller MK; Raptis DA; Hadaya K; Rüsi B; Laube G; Schneiter G; Fehr T; Villard J
Transplantation; 2010 Jul; 90(2):160-7. PubMed ID: 20658760
[TBL] [Abstract][Full Text] [Related]
56. Novel insights into pretransplant allosensitization in heart transplant recipients in the contemporary era of immunosuppression and rejection surveillance.
Svobodova E; Gazdic T; Kubanek M; Vymetalova J; Voska L; Kment M; Lanska V; Kolesar L; Urban M; Netuka I; Pirk J; Melenovsky V; Kautzner J; Slavcev A; Malek I
Transpl Int; 2016 Jan; 29(1):63-72. PubMed ID: 26340387
[TBL] [Abstract][Full Text] [Related]
57. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant.
Aubert V; Venetz JP; Pantaleo G; Pascual M
Hum Immunol; 2009 Aug; 70(8):580-3. PubMed ID: 19375474
[TBL] [Abstract][Full Text] [Related]
58. Association of C1q Binding Status With De Novo HLA Antibody Clinical Features and Allograft Function in Kidney Transplantation Patients During Eight Years of Dynamic Follow-up.
Wei X; Yuan X; Sun M; Pan Z; Hu L; Wang L; He J; Hou J
Transplant Proc; 2016; 48(6):1944-54. PubMed ID: 27569927
[TBL] [Abstract][Full Text] [Related]
59. Solid phase detection of C4d-fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients.
Bartel G; Wahrmann M; Schwaiger E; Kikić Ž; Winzer C; Hörl WH; Mühlbacher F; Hoke M; Zlabinger GJ; Regele H; Böhmig GA
Transpl Int; 2013 Feb; 26(2):121-30. PubMed ID: 23145861
[TBL] [Abstract][Full Text] [Related]
60. Relationship among C1q-fixing de novo donor specific antibodies, C4d deposition and renal outcome in transplant glomerulopathy.
Messina M; Ariaudo C; Praticò Barbato L; Beltramo S; Mazzucco G; Amoroso A; Ranghino A; Cantaluppi V; Fop F; Segoloni GP; Biancone L
Transpl Immunol; 2015 Sep; 33(1):7-12. PubMed ID: 26160049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
